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Background: Metabolic syndrome (MetS) is increasingly present in breast cancer survivors, possibly worsened by
cancer-related treatments, such as chemotherapy. MetS greatly increases risk of cardiovascular disease and diabetes,
co-morbidities that could impair the survivorship experience, and possibly lead to cancer recurrence. Exercise has been
shown to positively influence quality of life (QOL), physical function, muscular strength and endurance, reduce fatigue,
and improve emotional well-being; however, the impact on MetS components (visceral adiposity, hyperglycemia, low
serum high-density lipoprotein cholesterol, hypertriglyceridemia, and hypertension) remains largely unknown. In this
trial, we aim to assess the effects of combined (aerobic and resistance) exercise on components of MetS, as well as on
physical fitness and QOL, in breast cancer survivors soon after completing cancer-related treatments.
Methods/Design: This study is a prospective randomized controlled trial (RCT) investigating the effects of a 16-week
supervised progressive aerobic and resistance exercise training intervention on MetS in 100 breast cancer survivors.
Main inclusion criteria are histologically-confirmed breast cancer stage I-III, completion of chemotherapy and/or
radiation within 6 months prior to initiation of the study, sedentary, and free from musculoskeletal disorders. The
primary endpoint is MetS; secondary endpoints include: muscle strength, shoulder function, cardiorespiratory fitness,
body composition, bone mineral density, and QOL. Participants randomized to the Exercise group participate in 3
supervised weekly exercise sessions for 16 weeks. Participants randomized to the Control group are offered the
same intervention after the 16-week period of observation.
Discussion: This is the one of few RCTs examining the effects of exercise on MetS in breast cancer survivors.
Results will contribute a better understanding of metabolic disease-related effects of resistance and aerobic exercise
training and inform intervention programs that will optimally improve physiological and psychosocial health during
cancer survivorship, and that are ultimately aimed at improving prognosis.
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Recent estimates show that within the U.S. there are
more than 2.4 million breast cancer survivors with a
5-year survival rate of 88.6% [1]. These survivors are at
an increased risk of cancer recurrence, comorbidities
such as diabetes, osteoporosis and cardiovascular disease,
and premature death [2,3]. They also have special needs as
a consequence of the adverse effects associated with com-
mon treatments, such as surgery, chemotherapy, radiation
therapy, and endocrine therapy. One important conse-
quence of these adverse effects is a profound decline in
physical activity [4]. This is of particular concern as physical
activity is thought to lower the risk of cancer recurrence
and mortality [5]. Studies of survivors 6–12 months follow-
ing treatment describe individuals with decreased cardiore-
spiratory function, muscle strength, bone mineral density,
and physical well-being [6,7]. In addition, these survivors
experience fatigue, depression, anxiety, and weight gain
[8-10]. These effects of decreased physical activity appear to
have more profound effects on cardiovascular and psycho-
social health in those undergoing radiation and some forms
of chemotherapy [3,11]. While the effects between de-
creased physical activity and factors of overall well-being
has been established in moderate and long-term survivors
[12-15], less information is available with regards to ‘early’
(0–6 months post-treatment) survivors.
In 2012, the American Cancer Society released guide-
lines for cancer patients and survivors promoting physical
activity to improve cancer outcomes [16], emphasizing the
beneficial effects of exercise for the health of breast cancer
survivors. Not only has physical activity been associated
with decreased breast cancer risk [17-19], it has also been
shown to be beneficial for breast cancer survivors. For
example, aerobic exercise has been found to improve
cardiorespiratory function in survivors 6 months to 5 years
post-treatment [12,13,20,21], which is particularly import-
ant for survivors who have had cardiac damage from
chemotherapy. Resistance exercise has been found to
increase muscle strength [7,14,22,23], which subse-
quently reduces injuries and improves balance. Add-
itionally, combined (aerobic and resistance) exercise
programs result in improvements in cardiorespiratory
function and muscle strength in breast cancer sur-
vivors [24-26]. Combined exercise involves both re-
sistance and aerobic exercises in a single session and
therefore, is effective in improving cardiovascular,
musculoskeletal, and psychological health.
Current evidence suggests that breast cancer treatments,
such as chemotherapy, lead to weight gain and increased
adiposity, fatigue, physical inactivity, and negative alter-
ations in components of metabolic syndrome (MetS)
[4,10,27]. Metabolic syndrome (MetS), which is associ-
ated with increased risk of cardiovascular diseases and
type 2 diabetes (6), is a cluster of risk factors includingvisceral adiposity, hyperglycemia, low serum high-density
lipoprotein cholesterol, hypertriglyceridemia, and hyper-
tension [28]. MetS is highly prevalent and present in at
least 25% of American and European adults [29]. There-
fore, despite high breast cancer survival rates, many breast
cancer survivors are at risk of and may experience mortal-
ity from diabetes and cardiovascular disease, which can be
modified by lifestyle interventions [30,31]. Obese post-
menopausal breast cancer survivors receiving adjuvant
hormone therapy present with MetS and elevated levels
of C-reactive protein, placing them at a higher risk for
cardiovascular and metabolic diseases [27,32,33]. Pre-
menopausal breast cancer patients experience detrimental
effects such as increased body mass index (BMI) and
central obesity from adjuvant chemotherapy potentially
contributing to MetS [34]. Chemotherapy in premeno-
pausal breast cancer patients frequently induces prema-
ture menopause, which is associated with increases in
body fat, cholesterol, and triglycerides [34,35]. These
changes may contribute to earlier development of car-
diovascular disease or type 2 diabetes among women
already at risk or to increased risk among those not
already predisposed to these diseases [28].
Treatment and management of MetS mainly consists
of symptomatic drug treatments of the syndrome’s indi-
vidual components [36]. Candidate drugs that reduce
hyperglycemia may have additional metabolic benefits.
Examples are metformin, currently being evaluated in a
large randomized adjuvant trial for early stage breast
cancer [37], PPARγ agonists, GLP-1 agonists, and DPP-
4 inhibitors [36,38]. However, since lifestyle factors such
as physical activity, dietary intake, and smoking habits
affect the risk of developing MetS, it is important and
possibly preferable to target lifestyle factors to prevent
the onset of metabolic-related diseases in breast cancer
survivors. The few studies that have examined the
effects of exercise training on particular components of
MetS in postmenopausal breast cancer survivors have
shown reduced insulin levels and waist circumference,
but no change in insulin resistance, fasting glucose, or
body weight [39,40]. Some of these results are promis-
ing and emphasize the need for additional studies in
this area. Studies of premenopausal survivors will be par-
ticularly important. Given that chemotherapy induces many
of the components of MetS, an effort to offset potential
treatment side effects can greatly benefit breast cancer
patients.
This trial is a prospective, randomized controlled trial
(RCT) in breast cancer survivors following chemotherapy
and/or radiation treatments exploring the effects of a
16-week supervised progressive combined (aerobic and
resistance) exercise intervention on components of MetS
(visceral adiposity, glucose, high-density lipoprotein cho-
lesterol, triglycerides, and blood pressure), as well as
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Objectives
The primary objective of this trial is to determine the ef-
fects of a 16-week combined exercise intervention on com-
ponents of metabolic syndrome (MetS) including waist
circumference, blood pressure, fasting glucose, HDL, tri-
glycerides, and glucose, compared to a usual care control
group among breast cancer survivors. Secondary objectives
are to determine the effects of exercise on cardiorespiratory
fitness, muscle strength, body composition, quality of life,
shoulder strength and range of motion (ROM), and serum
levels of insulin, C-reactive protein, and glycosylated hemo-
globin (HbA1c). Safety and feasibility of the supervised
exercise program will be evaluated, and the sustainability of
the effects will be assessed.
Methods/Design
Study design
This RCT targets women with stage I-III breast cancer fol-
lowing radiation and/or chemotherapy treatments. After
obtaining written consent, participants are randomized to
a supervised combined (aerobic and resistance) exercise
program over 16 weeks (Exercise Group) and usual care
(Control Group; see Figure 1). Endpoints are assessed at
baseline (T1), after the end of the 16-week intervention
(T2), and 12 weeks post-intervention (Exercise Group
only; T3; see Figure 2).
To enhance participation rate and maintain high compli-
ance to the intervention scheme, participants in the Control
group are offered the exercise program following the study
period. Participants in the Exercise group are supervised by
a certified exercise specialist to ensure a tailored, perso-
nalized program is executed. The exercise intervention is
based on a previously utilized program deemed safe and
effective in breast cancer survivors [40].
This study was approved by the Institutional Review Board
of the University of Southern California (HS-12-00141) and
is registered at ClinicalTrials.gov (NCT01140282).Figure 1 Study design. Endpoints are assessed at baseline (T1), after the e
(Exercise Group only; T3).Participant selection
This trial includes women with histologically con-
firmed Stage I-III primary breast cancer who have
recently completed all cancer-related treatments and
who do not have any contraindications for moderate
exercise. Inclusion and exclusion criteria are provided
in Table 1.
Recruitment and randomization
All eligible breast cancer patients scheduled for chemo-
therapy and/or radiation at the USC Norris Compre-
hensive Cancer Center (NCCC) or Los Angeles County
Hospital are briefly informed about the trial during their
medical oncology or surgical oncology appointments. If
interested, patients are then informed in detail about the
trial by the study principal investigator and inclusion/ex-
clusion criteria are verified. For each patient recruited into
the study, written informed consent is obtained prior to
performing randomization or outcome measure testing.
Upon written informed consent, the patient is randomly
assigned to either the Exercise or Control groups, and
scheduled for the baseline visit, which should be within
0–24 weeks of completing chemotherapy and/or radiation.
Randomization (intervention assignment) is done by the
Clinical Investigation Support Office (CISO) at the USC
NCCC; study investigators contact CISO once the partici-
pant has signed the informed consent and is registered.
To randomly assign the intervention arm to patients, 2
randomization lists are prepared in advanced to accom-
modate the stratification: one for pre-menopausal partici-
pants and one for post-menopausal participants, based on
their menopausal status at time of cancer diagnosis. The
randomization is based on a permuted block design with
block size of 10. Stratification is used in the randomization
process, as we expect menopausal status to have a major
influence on our study outcomes. To prevent possible
bias, study personnel involved in the recruitment do not
have access to the randomization lists. Conversely, the
biostatistician does not have influence on the recruitment
procedure.nd of the 16-week intervention (T2), and 12 weeks post-intervention
Figure 2 Study flow.
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Participants in the Exercise group participate in the
exercise program three times per week for 16 weeks for
approximately 60 minutes per session, totaling 48 sessions.
Participants train one-on-one with a Certified American
College of Sports Medicine/American Cancer Society
(ACSM/ACS) Cancer Exercise Trainer for each session.
Aerobic exercise duration per session is increased by 5 mi-
nutes every 3-4 weeks resulting in a total of 45 minutes of
aerobic exercise per session by week 16 of the interven-
tion. The trainer documents attendance of each partici-
pant at each session. If sessions are missed, reasons are
documented with make-up sessions allowable extending
the program to a maximum of 18 weeks.
Sessions are comprised of machine- and free weight-
based resistance exercise and aerobic exercise at the
Clinical Exercise Research Center (CERC) in the Division
of Biokinesiology and Physical Therapy at USC. Estimated
one-repetition maximum (1-RM) and estimated VO2maximum obtained during baseline testing is used to
determine resistance load for each exercise and aerobic
intensity, respectively. The exercise program (Table 2)
complies with American College of Sports Medicine
(ACSM) exercise guidelines for cancer survivors, which
includes 20–60 minutes of aerobic exercise performed
at least 3 times per week and 6–10 resistance exercises
performed at least 1–3 days per week [41-43]. Participants
are required to wear a Polar® heart monitor (Lake Success,
NY) during each exercise session. Heart rate (HR) is
monitored throughout the aerobic exercise sessions to
maintain an exercise HR at 65-80% of maximum HR.
This protocol is designed to include moderate-to-vigorous
forms of activity, which are more beneficial in decreasing
risk of mortality from breast cancer, cardiovascular disease
and diabetes [30,31,44]. Aerobic exercise types include
treadmill walking, jogging, hill walking, or stationary cyc-
ling. Each resistance exercise session includes the follow-
ing exercises: 1) leg press; 2) lunges; 3) leg flexion; 4) leg
extension; 5) chest press; 6) seated row; 7) biceps curls;
and 8) triceps pushdown. Initial resistance is set at 80% of
the estimated 1-repetition maximum (1-RM) for lower
body exercises and 60% 1-RM for upper body exercises.
When the participant is able to complete 3 sets of 10 repe-
titions at the set weight in 2 consecutive sessions then the
weight is increased by 10%. Participants with a compres-
sion garment were required to wear the garment during
the exercise sessions. Each daily session begins with a
5 minute warm up on the treadmill or cycle and 10 mi-
nutes of static stretching.
Follow-up period
After the 16-week intervention period has ended, partic-
ipants in the Exercise group are asked to return to the
CERC 12 weeks later to repeat the outcome measure
testing. During the 12-week period, participants are en-
couraged to exercise on their own without study team
supervision. This can be independent or group activity
and participants may seek assistance from fitness profes-
sionals as they see fit. The participants are asked to
maintain weekly physical activity logs and wear a ped-
ometer on a daily basis during this period. The purpose
of this follow-up period is to determine whether the par-
ticipants remain active and can maintain the benefits
gained from the exercise intervention.
Outcome measures
The outcome measures tested in the study are summa-
rized in Table 3.
Metabolic syndrome
The primary endpoint is change in the components of
metabolic syndrome (MetS) from baseline to week 17.
MetS is comprised of 5 components: hypertension, high
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Women with primary breast cancer, stage I-III • History of chronic disease (i.e., diabetes, uncontrolled hypertension,
thyroid disease)
• ≥ 18 years of age • Weight reduction > 10% within past 6 months
• Have undergone lumpectomy or mastectomy • Metastatic disease
• Have completed neoadjuvant/adjuvant chemotherapy
and/or radiation therapy
• Planned reconstructive surgery with flap repair during trial or
follow-up period
• Initiate exercise program (if randomized to that arm)
within 24 weeks of therapy completion
• Cardiovascular, respiratory, or musculoskeletal or joint problems
that preclude moderate physical activity
• BMI≥ 25 kg/m2 or body fat > 30%
• Currently participates in < 60 minutes of physical activity per week
• May use adjuvant endocrine therapy if use will be continued for
duration of study period
• Nonsmokers (No smoking during previous 12 months)
• Willing to travel to USC
Able to provide physician clearance to participate in exercise
program
• Women of all racial and ethnic backgrounds will be included in
the study enrollment process
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vated triglycerides; an individual is diagnosed with MetS
if they present with 3 out of the 5 components [45].
Therefore, at each time point, the 5 MetS components
are assessed individually and each participant is given a
score out of 5 based on the criteria used to determine
whether each component lies within the normal range.
The following criteria was used to score MetS: 1) blood
pressure > 130/85; 2) waist circumference > 35 inches; 3)
triglycerides ≥ 150 mg/dL; 4) HDL < 50 mg/dL; 5) glucose
≥ 100 mg/dL. Upon study completion, we will analyze
changes in each component as well as the cumulative
score.Venipuncture
Fasting blood (~30 cc) is drawn from the antecubital
vein by trained phlebotomists at the Clinical Exercise
Research Center (CERC). Participants are asked to fast
for 12 hours prior to the blood draw. Refreshments are
provided following the blood draw and prior to proceed-
ing with further testing.Table 2 Combined exercise intervention
Day 1 Day 2 Day 3 Day
Aerobic exercise: 30 minutes
at 65-80% HR maximum;
Resistance exercise: 3 sets of
10 repetitions, 45 second rest
between sets
Rest Aerobic exercise: 30 minutes
at 65-80% HR maximum; No
resistance exercise
RestBiomarkers
The Diabetes and Obesity Research Institute (DORI) at
the USC performs appropriate standard assays to
measure serum lipids (cholesterol, HDL-cholesterol,
LDL-cholesterol, triglycerides), insulin, glucose, high
sensitivity C-reactive protein (CRP), and glycosylated
hemoglobin (HbA1c) from the peripheral blood samples.
Fasting glucose, insulin, and HbA1c serve as metabolic
biomarkers while CRP serves as an inflammatory bio-
marker [27]. Serum is derived from whole peripheral
blood samples, processed within 2 hours after taking the
blood sample and stored at −80° for analyses of bio-
markers after completion of last study participant.Waist circumference
A tape measure is used to obtain waist circumference
measured at the midpoint between the lower margin of
the last palpable rib and the top of the iliac crest. Hip
circumference is measured, around the widest portion of
the buttocks, with the tape parallel to the floor, to deter-
mine waist-hip ratio.4 Day 5 Day 6 Day 7
Aerobic exercise: 30 minutes at
65-80% HR maximum; Resistance
exercise: 3 sets of 10 repetitions,
45 second rest between sets
Rest At-home aerobic exercise:
30 minutes at 65-80% HR
maximum
Table 3 Assessments and instruments used
Outcomes Instrument T1 T2 T3
Primary endpoint
Components of MetS (5): X X X
Biomarkers- Glucose, HDL, triglycerides Analyzed in peripheral blood X X X
Blood pressure Pressure cuff under resting conditions X X X
Waist circumference Measuring tape X X X
Secondary endpoints
Cardiorespiratory fitness 4-minute walk test X X X
Muscle strength 10-RM- leg extension, leg flexion, chest press, seated row X X X
Body composition DEXA, weight, height, lean mass, % body fat, hip circumference X X X
Quality of life SF-36, FACT-B, CES-D X X X
Shoulder strength Muscle force for SE and ER X X X
Shoulder ROM Measured with goniometer at 90° ER, forward flexion, X X X
Upper limb musculoskeletal disorder
assessment
DASH, PSS X X X
Biomarkers- inflammation & endocrine
function
Analyzed in peripheral blood X X X
Others
Breast cancer characteristics Family history, TNM status, ER/PR status, HER-2 score X
Medical history Recording of any pre-existing disease and allergies X
Treatment data Pre-treatment: date and type of breast cancer, affected lymph nodes,
chemotherapy type and dose, radiation- technique, type, dose, start/stop
date, hormone therapy
X
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The participant is asked to sit quietly for 5 minutes
while resting her arm (ipsilateral to the affected breast)
on a table so the brachial artery is level with the heart. A
sphygmomanometer cuff is wrapped around the partici-
pant’s upper arm, just above the elbow and a stethoscope
is placed on the hollow of the elbow so blood pressure
can be measured.Physical fitness
All fitness measures are performed by trained study
personnel at the CERC.Cardiopulmonary fitness
A single-stage submaximal treadmill test is used to esti-
mate maximal oxygen uptake [46]. Cardiopulmonary fit-
ness testing is well established in cancer patients and
recommendations for testing procedures as well as safety
guidelines in clinical trials with cancer populations have
been well defined [47]. The procedure is also used to ex-
clude exercise-contraindicating cardiac impairments.
Participants are instructed to walk so they are able to
talk while walking at a speed of 2.0, 3.0, 4.0, or 4.5 mph
on a treadmill (Desmo Woodway, Waukesha, WI) for
4 minutes at a 5% grade and heart rate is measured at
the end of the test. Using HR, speed, age and gender,maximal oxygen uptake is calculated using the specific
formula that applies to this test.
Muscle strength
Maximal voluntary strength is evaluated by the 10-repe
tition maximum (10-RM) method for the following exer-
cises: chest press, latissimus pulldown, knee extension, knee
flexion, (Tuff Stuff, Pomona, CA) which will be used to cal-
culate 1-RM (maximum strength) values for the exercise
intervention [48]. The study personnel demonstrate each
exercise and then the participant is asked to complete 5
repetitions of a light weight to ensure proper form. The
participant rests for 30 seconds and then is asked to lift a
heavier weight 10 times. This is repeated until the partici-
pant is no longer able to complete 10 successful repetitions.
Body composition
BMI in kg/m2 is calculated from height and weight mea-
surements obtained using a medical scale (Detecto® 437,
Webb City, MO). Body composition (total lean mass
and percent body fat) is measured from a whole body
scan using Dual-Energy X-ray Absorptiometry (DXA,
GE iDXA, Fairfield, Connecticut) and with bioelectrical
impedance analysis (BIA, Biospace InBody 520, Cerritos,
CA). The DXA is considered to be a valid and reliable
reference method for body composition assessment
[49]. BIA is a quick and non-invasive method, which
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flow of an electric current through body tissues to calcu-
late an estimate of total body water, fat-free mass and
body fat [50]. We chose to include the DXA and BIA to
assess ability to use more portable techniques such as
BIA for future studies and to better determine possible
differences between the two devices in this population.
Shoulder health and lymphedema measures
Shoulder strength
Maximal muscle force produced by the primary agonist
during scapular plane elevation (SE) and external rota-
tion (ER of the upper extremity are measured using a
hand held dynamometer (HHD; Hoggan Health Indus-
tries, Salt Lake City, UT). The participant sits in an arm-
less chair with her back flush to the back of the chair,
feet flat on the floor approximately shoulder width apart,
and sitting with neutral posture. The participant is
asked to push as hard as possible against the HHD for
approximately 4 seconds. For each test (SE and ER), the
dynamometer on the apparatus is aligned so that the
resistance is in exactly the opposite direction of the dir-
ection of motion being resisted. Two trials are per-
formed for each muscle test, taken sequentially. The
subject is allowed to rest for 30 seconds between the
two trials. The average of two trials is used for data ana-
lysis. Shoulder strength is regularly assessed in breast
cancer survivors as a means to determine effects of
surgery and treatment-related side effects [51] and is
measured following our exercise intervention.
Shoulder active range of motion (AROM)
AROM is measured for shoulder forward flexion and
shoulder ER at 90 degrees abduction.
ER at 90 degrees of abduction The participant is
placed in supine, trunk stabilized on the table, knees
bent so that the feet are placed flat on the table. The
participant’s arm is placed in 90 degrees of shoulder
abduction, the elbow flexed to 90 degrees, and the wrist
in neutral position. The participant’s arm is passively
moved into external rotation within their pain-free range
of motion 3–5 times to precondition the tissue. Then,
the participant is asked to perform active ER where ‘active’
refers to the participant moving their own arm through
the ROM independent of tester assistance. Active ER is
measured with the Acumar™ digital inclinometer aligned
between the olecranon and ulnar styloid process to meas-
ure external rotation of the glenohumeral joint. Two trials
are performed with approximately 10 seconds between
each trial.
Forward flexion The participant is placed in a standard-
ized seated position, with their back directly against theback of a straight back chair. Participants are asked to
actively elevate their arm as far as they can into flexion.
The Acumar™ digital inclinometer is aligned along the
mid-humeral shaft with the elbow in extension and
shoulder in neutral rotation by asking the subject to
point their thumb towards the ceiling. Two trials are
performed with approximately 10 seconds between each
trial.
Lymphedema assessment
Geometric arm volume calculations are performed to
assess lymphedema. We are calculating arm volume
using circumferential measurements taken at anatomic
landmarks and was determined to be a reliable and valid
method of limb volume measurement [52]. The partici-
pant is seated at a table with their shoulder positioned at
approximately 90° of scapular plane flexion with their
straight arm resting on a table. Circumferential measure-
ments will be taken with a thin plastic tape measure
with a spring that standardizes how tightly the tape is
pulled. The anatomic landmarks include the wrist to
middle forearm, middle forearm to elbow, elbow to mid-
dle upper arm, and middle upper arm to a 65% mark.
The 65% mark of the upper arm is 65% of the distance
from the elbow (olecranon) to the shoulder tip (acro-
mion). Calculations for limb geometric volume will be
calculated using the frustum volume as described by
Taylor et al. [52] The interrater reliability for this
method has been found to be excellent (>0.98)23. A per-
centage difference between lymphedema limb and the
uninvolved limb will be calculated to determine the
amount of lymphedema. Lymphedema has been defined
in recent literature as a greater than 10% difference in
volume calculation for the arm compared to the unin-
volved upper extremity [52].
Participant-reported outcomes
Physical activity assessments
Physical activity history is assessed at baseline using an
interviewer-administered physical activity questionnaire
[53]. Throughout the duration of the study period, weekly
7-day physical activity logs [54] are completed by all par-
ticipants and returned to the PI by mail for the Control
group.
Dietary assessments
Dietary history is measured at baseline using the NIH-
DHQ food frequency questionnaire [55]. Three-day dietary
records are completed at baseline and at the completion of
the study period to assess recent dietary patterns.
Quality of life assessments
Quality of life (QOL) is assessed using the SF-36 and
FACT-B. The SF-36 is a multi-purpose, short-form health
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health [56]. The FACT-B (Functional Assessment of
Cancer Therapy-Breast) is a breast cancer-specific ques-
tionnaire comprised of 44 items to specifically assess
quality of life in breast cancer patients [57].Psychosocial assessments
Depressive symptoms are assessed using the 20-item CES-
D (Center for Epidemiologic Studies Depression) scale,
which was designed to measure current level of depressive
symptomatology [58].Musculoskeletal disorders assessment
Upper limb musculoskeletal disorders is assessed using
the DASH (Disabilities of the Arm, Shoulder, and Hand)
and Penn Shoulder Scale (PSS). DASH is a 30-item ques-
tionnaire designed to measure physical function and
symptoms of possible musculoskeletal disorders of the
upper limb [59]. The PSS is a 100-point shoulder-specific
self-report questionnaire consisting of 3 subscales of pain,
satisfaction, and function [60].Tracking and monitoring of adverse events
Potential adverse events (e.g., lymphedema, pain, muscle
soreness, nausea, etc.) are assessed, graded and attrib-
uted using CTCAE, v4.3 and recorded by the exercise
trainer at each training session by standardized question-
naires throughout the intervention period. Adverse events
reported spontaneously by the patient or observed by
study nurses or physicians are similarly assessed and
recorded.Sample size
The primary aim is to compare changes in overall MetS
scores from baseline to week 17 between the Exercise
and Control groups. Since MetS has not been investigated
in breast cancer survivors at the time of project initiation,
we chose to calculate sample size using changes in insulin
following exercise in breast cancer survivors. This project
is designed to detect a treatment effect based on insulin
results with 80% statistical power at a 5% level of statistical
significance. Ligibel et al. assessed insulin levels before
and after a 16-week exercise intervention in breast
cancer survivors [40]. Using their results, a sample size
of 80 participants would detect a difference in mean
insulin levels of 2.6 μU/ml assuming that the common
standard deviation is 4.0 μU/ml using a two group t-test
with two-sided 5% level of statistical significance. There-
fore, to allow for a 20% maximum withdrawal rate, 100
participants will be recruited, of whom 50 will be premen-
opausal and 50 postmenopausal.Data analysis
The main intervention effect will be assessed on the
basis of a comparison between exercisers and controls as
defined at randomization, regardless of exercise adher-
ence, i.e., according to intent-to-treat principle. A 2
(group) × 2 (time) repeated measures analysis of vari-
ance (ANOVA) will be used to examine changes in MetS
score and for each individual component of MetS. Strati-
fication by type of therapy (i.e., surgery, chemotherapy,
radiation) may result based on therapy regimens com-
pleted by enrolled subjects. Similar analyses as for MetS
will also be performed for the secondary endpoints. Cor-
relation analyses will be used to examine the relationship
between changes of the various measured endpoints.
Regression analyses regarding the repeated measurement
design (T1, T2, T3) will be applied to investigate the asso-
ciation between exercise intervention, MetS, cardiopulmo-
nary fitness, muscle strength, body composition, and the
QOL dimensions. The influence of other potential con-
founding factors, such as age, clinicopathologic character-
istics, and comorbidities will be explored and accounted
for in the analysis. In addition, change in physical activity
behavior post intervention will be explored for the follow-
up time points using descriptive analysis.Discussion
The present study will contribute to the growing field of
exercise in breast cancer survivors with respect to several
innovative aspects being tested: 1) Examining MetS com-
ponents collectively following exercise; 2) progressive
combined exercise training; 3) inclusion of premenopausal
women; 4) inclusion of ‘early’ breast cancer survivors; 5)
sustainability effects of 16-week exercise intervention.
Therefore, the results of this study will help inform
future more definitive trials powered for disease-free
and overall survival as to what indices at baseline or
following an exercise program might be predictive of
long-term benefit, and how might future programs be
individualized for maximal benefit.
With the improvement of survival rate, the impact of
comorbidity on survival and quality of life among breast
cancer survivors has become an important topic. MetS
is an established risk factor for cardiovascular diseases
and mortality [28,61]. Emerging evidence implicates
MetS as a long-term risk factor for cancer, but also that
certain cancer therapies might increase risk of develop-
ing MetS among cancer survivors [62-64]. The concern
for MetS and related risk factors among breast cancer
survivors has attracted growing attention [63]. Previous
studies have shown that high levels of exercise are in-
versely correlated with the prevalence of MetS in the
general population [65-67]. However, whether exercise
participation can reduce the risk of MetS among cancer
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inversely associated with development of MetS in child-
hood cancer survivors [68]. Data among breast cancer
survivors are scarce. To our knowledge, only one study
specifically evaluated the association between exercise and
MetS among breast cancer survivors and found that exer-
cise participation between 6 and 60 months post-diagnosis
was inversely associated with the prevalence of MetS for
exercise participation ≥ 3.5 hours/week (30 min/day; OR
0.69, 95% CI 0.48-0.98) [69]. Thus, observational evidence
supports benefits of exercise to attenuate MetS and our
current trial will determine whether a supervised exercise
intervention will result in improved MetS components.
To date there are over 157 ongoing or completed clin-
ical trials involving exercise and breast cancer survivors
reported on ClinicalTrials.gov, demonstrating the grow-
ing importance of the health and quality of life benefits
of exercise for breast cancer survivors. Physiologically, to
attenuate MetS in non-cancer persons, implementing a
strictly aerobic exercise program has been found effect-
ive since aerobic exercise can reduce blood pressure,
decrease triglycerides, improve insulin sensitivity, and
body fat [70-73]. However there is additional evidence to
support the use of resistance exercise to improve insulin
sensitivity and glucose tolerance [74-76]. Thus, to inves-
tigate effects of exercise on components of MetS, we de-
signed a progressive combined exercise intervention,
which includes both aerobic and resistance exercises.
Due to benefits of resistance exercise on muscular
strength, balance, and bone density, it is critical to the
health of our participants to include both resistance and
aerobic exercise. Although a limited scope of research is
available to describe specific exercise needs of these sur-
vivors, a recent report addresses this topic in rural breast
cancer survivors [77]. This indicated that survivors pre-
fer to receive face-to-face exercise counseling from an
exercise specialist anytime before or after treatment.
Accommodating this need is achieved in our present
study as we are providing face-to-face exercise instruc-
tion soon after treatment is completed in an effort to
enhance sustainability of the exercise program by dem-
onstrating that expensive equipment and extraneous
costs do not have to be associated with an exercise. Sig-
nificant value is placed on exercise by survivors who
may or may not participate in exercise as means of
health promotion and support [78] which reiterates the
importance of exercise and the need for a feasible exer-
cise program to encourage participation in exercise.
Our trial includes a unique population of breast cancer
survivors, regarding age and ethnicity. The few studies
that have examined the effects of exercise training on
particular components of MetS have involved postmeno-
pausal breast cancer survivors [39,40]. Premenopausal
breast cancer survivors are understudied and may beparticularly important due to the different hormonal mi-
lieu from postmenopausal women. At USC, particularly
the Los Angeles County hospital, approximately 50% of
all breast cancer cases are premenopausal, increasing the
feasibility of included premenopausal women. Statistically,
we will stratify by menopausal status in order to determine
if the effects of our trial varies among premenopausal and
postmenopausal women. USC treats a diverse population
of patients and is conveniently located in the East Los
Angeles section of Los Angeles County also near the San
Gabriel Valley. East Los Angeles and the neighboring San
Gabriel Valley, with a population of approximately 2.5
million people, is distinct in that it contains a large con-
tingency of Hispanics (34%), Asian Americans (20%)
and African Americans (15%) who vary widely in socio-
economic position [79]. Additionally, LA-USC County
Medical Center welcomes patients with Medi-Cal cover-
age, which is California’s low income Medicaid program.
Overall, breast cancer patients who receive care at USC
are 30% Latina, 20% Asian/Pacific Islanders, 30% White,
15% African American and 5% other. Thus, we will have
the ability to recruit from a diverse patient pool, with
currently 90% of our patient population is comprised of
Latina survivors.
Timing of an intervention is a key aspect in order to
capture a time point following treatment where survi-
vors change their lifestyle behaviors, often referred to as
the “teachable moment [80]”. Currently, the optimal
time to participate in an exercise intervention following
breast cancer diagnosis is unknown. Capitalizing on the
“teachable moment” soon after treatments by enrolling
in a supervised exercise program will foster a behavioral
change that will be sustainable for longer periods of time
due to the positive and encouraging environment elic-
ited through exercise. Breast cancer survivors may be
more likely than other cancer survivors to harbor psy-
chological stress of a diagnosis for longer periods of time
and may have higher levels of interest in interventions
[81], stressing the importance of an early intervention,
supporting our inclusion of ‘early’ breast cancer survi-
vors. ‘Early’ breast cancer survivors include women who
have completed all cancer-related treatments within
0–6 months of study entry. Since many exercise trials
have included survivors from 6 months- 10+ years post-
treatment [82], we believe it was critical to include survi-
vors who more recently completed treatment to capitalize
on the teachable moment.
A unique component of this study is the inclusion of a
12-week follow-up period of the Exercise group after
completion of the trial to measure longer-term adherence.
Numerous cancer-related exercise interventions have
failed to examine whether the benefits of the intervention
persist following study completion despite reporting high
(>80%) adherence rates [83,84]. This is an important
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diminish due to failure of the participants to maintain a
regular exercise program following study completion.
Although many exercise interventions strive to instill a
behavioral change to a more physically active lifestyle,
there is a lack of data on post-intervention adherence.
This study will determine whether the positive benefits of
exercise can be maintained following a 12-week follow-up
period where participants will not be actively enrolled in
an investigator-led exercise intervention. Critical informa-
tion in regards to diet and physical activity patterns and
effects on MetS will be obtained during this period which
will provide novel information for future intervention
studies to achieve the goal of long-term adherence.
Conclusion
In summary, this exercise trial shall contribute to a
better understanding of metabolic-related effects of
combined aerobic and resistance exercise in breast
cancer survivors who have recently completed cancer-
related treatments. The ultimate goal is the implemen-
tation of an optimized intervention program to reduce
metabolic syndrome and prevent cardiovascular dis-
ease and diabetes during survivorship.
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